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Abstract
Background—African Americans (AA) have lower triglycerides (TG) and higher high density 
lipoprotein-cholesterol (HDL-C) than other ethnic groups yet they also have higher risk for 
developing diabetes mellitus despite the strong relationship of dyslipidemia with insulin 
resistance. No studies directly compare adolescents and adults with regard to relationships 
amongst dyslipidemia, C-reactive protein (hsCRP), and insulin resistance. Here we compare AA 
adolescents to adults with regard to the relationships of adiposity-related lipid risk markers 
(TG/HDL ratio and non HDL-C) with body mass index (BMI), waist circumference (WC), 
homeostasis model of insulin resistance (HOMA), and hsCRP.
Methods—Two cohorts of healthy AA were recruited from the same urban community. 
Participants in each cohort were stratified by TG/HDL ratio (based on adult tertiles) and non-
HDL-C levels. BMI, WC, HOMA and hsCRP were compared in adolescents and adults in the low, 
middle and high lipid strata.
Results—Prevalence of TG/HDL ratio greater than 2.028 (high group) was 16% (44/283) in 
adolescents and 33% (161/484) in adults; prevalence of non HDL-C above 145 and 160 
respectively was 8% (22/283) in adolescents and 12% (60/484) in adults. HsCRP values were 
lower and HOMA values were higher in adolescents (both p < 0.01). As both TG/HDL ratio and 
non HDL-C strata increased, BMI, WC, HOMA, and hsCRP increased in both adolescents and 
adults. In the high TG/HDL and non HDL-C groups, BMI and WC were similar in adolescents vs. 
adults (BMI 34 kg/m2 vs 32 kg/m2; WC 101 cm vs 101 cm). After adjusting for non-HDL-C and 
other covariates, a 2-fold increase in TG/HDL was associated with increases of 10.4% in hsCRP 
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(95% CI: 1.1% – 20.5%) and 24.2% in HOMA (95% CI: 16.4% – 32.6%). Non-HDL-C was not 
significant in models having TG/HDL.
Conclusions—Elevated TG/HDL ratio is associated with similar inflammation and metabolic 
risk relationships in adolescent and adult African-Americans.
Keywords
triglycerides; HDL cholesterol; obesity; inflammation; insulin resistance; risk factors
Introduction
Obesity, dyslipidemia, insulin resistance and inflammatory markers such as C-reactive 
protein (hsCRP) are strongly associated and together increase risk for metabolic and 
cardiovascular disease. Elevated serum triglyceride (TG) and serum lower high density 
lipoprotein (HDL) are associated with measures of insulin resistance and both lipid 
measures are components of metabolic syndrome.[1] The TG/HDL ratio has been shown to 
be a strong marker for cardiovascular risk and metabolic syndrome in obese children and 
adults [2–6] Non-HDL cholesterol (non-HDL-C) has also been shown to be strongly 
associated with the metabolic syndrome in children and reflects the concentration of 
atherogenic lipoproteins[5, 7]. Non-HDL-C is reported to be the best predictor of adult 
dyslipidemia and other cardiovascular risks. [8, 9] Insulin resistance is commonly associated 
with obesity in children and adolescents and has been shown to lead to decreased clearance 
of TG and Low density lipoprotein (LDL), overproduction of very low density lipoprotein 
(VLDL), and therefore decreased production of HDL [10–12]. However, direct comparisons 
between adults and children to determine if there is a difference in the magnitude of 
association with regard to these traits across the lifespan has not been previously studied.
Health related disparities have been identified in adult ethnic minority populations including 
African Americans[13, 14]. Ethnic differences in cardiovascular disease outcomes are 
apparent and important to consider. Compared to Caucasians, African American adults 
suffer higher rates of obesity and diabetes with disproportionally greater rates of of the 
premature cardiovascular morbidity and mortality. The Bogalusa Heart Study, which 
enrolled African American and Caucasian youth, demonstrated that many metabolic 
parameters, such as obesity, high blood pressure and lipid abnormalities tracked from 
childhood into adulthood. Although the trends were the same for African Americans and 
Caucasians, there was a higher prevalence of these risk factors in African Americans [15, 
16]. Associations of elevated TG and low-HDL-C exist among both ethnic groups, but the 
magnitude is different from one ethnic group to another. African Americans have lower TG 
and higher HDL-C levels, compared to their Caucasian counterparts and this is observed in 
both children and adults [6, 17, 18]. Nonetheless, African American girls are observed to 
have higher body mass index (BMI) and greater insulin resistance compared to Caucasian 
girls of the same age [19]. Despite higher prevalence of insulin resistance, the phenotype of 
hypertriglyceridemia and low HDL-C are observed less frequently in African Americans of 
all ages[17].
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Since TG/HDL ratio and non-HDL-C are strongly associated with insulin resistance and 
inflammation, we stratified adolescent and adult African Americans by these measures to 
determine if associations with BMI, waist circumference (WC), hsCRP, and the homeostasis 
model of insulin resistance (HOMA) were similar in the two age groups. These comparisons 
will inform discussions about metabolic risk across the lifespan.
Methods
Cohort
Adolescent and adult studies enrolled African Americans (based on self report) from the 
same urban community. The adolescent study enrolled participants between ages 13–18 
years of age from 2009–2011. The adolescent study enrolled participants for a study 
designed to compare those with and without high blood pressure (BP; >120/80mmHg) and 
with and without obesity (defined as BMI >95th percentile) in a 2 × 2 design.[20] The 
adolescents were recruited from primary care pediatrics and family practices at Thomas 
Jefferson University and from community primary care practices. Exclusion criteria for 
adolescent participants were known diabetes, secondary hypertension, stage two 
hypertension, renal disease and other chronic diseases. This study protocol was approved by 
the Institutional Review Board of Thomas Jefferson University and the A.I. DuPont Hospital 
for Children. Written and informed consent was obtained from those 18 years old. Parent or 
guardian informed consent was obtained for adolescents under age 18.
Adults were between the ages 19–45, recruited from family practices at Thomas Jefferson 
University and from community primary care practices, and data were collected between 
2006 and 20010. All the participants were without chronic health problems with the 
exception of elevated BP (>130/85mmHg) or receiving antihypertensive medication in 
approximately half the participants and obesity in half of the participants. Individuals with 
known diabetes or other chronic diseases were excluded from the adult study. The study 
protocol was approved by the Institutional Review Board of Thomas Jefferson University. 
Written informed consent was obtained from each participant at the time of the enrollment.
Study Methods
Similar methods and procedures were applied to both adolescent and adult studies. These 
methods have been published in other reports.[20, 21]. Data on health status, medication use 
and health related behaviors were obtained by self-report. Clinical assessment included BP 
and anthropometric measurements (height, weight and WC). BMI was calculated (weight in 
kilograms divided by height in meters squared). For the adolescent cohort, obesity was 
defined as BMI as >95th percentile by CDC criteria (http://www.cdc.gov/obesity/childhood/
defining.html).
A fasting blood sample was obtained for glucose, insulin, lipids, and hsCRP. Glucose was 
measured by the glucose oxidase technique (YS model 27; Glucostat, Yellow Springs, 
Ohio). Samples of fasting plasma were stored frozen (−80 degrees C) for later assay of 
insulin and hsCRP. Plasma insulin concentration was assayed using a solid phase 
radioimmunoassay,(Coat-a-Count; Diagnostic Products Corp, Los Angeles, California). 
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Assay for hsCRP was performed using an elisa kit from R&D Systems (Minneapolis, MN). 
Insulin resistance was estimated using HOMA[22]. Fasting lipids were measured including 
TG, HDL-C, and total cholesterol with LDL-C calculated. Lipids were measured using the 
Hitachi 704 standard enzymatic method in the Lipid laboratory at Thomas Jefferson 
University
Statistical Methods
Subjects in each age range were stratified into groups by tertiles of TG/HDL: low (TG/HDL 
<= 1.136), middle (1.136< TG/HDL <= 2.028) and high (TG/HDL > 2.028). Adolescents 
were stratified into tertiles according to nonHDL-C strata: low (nonHDL-C <120), middle 
(120< nonHDL -C< 145) and high (nonHDL-C >=145). Subjects in the adult cohort were 
also stratified into tertiles according to nonHDL-C strata: low (nonHDL-C <130), middle 
(130< nonHDL -C< 160) and high (nonHDL-C >=160). The non HDL-C strata were based 
on ATP III/NHLBI expert guidelines.[23, 24] Adolescents and adults in the low, middle and 
high strata were compared with regard to BMI, WC, HOMA, and hsCRP.
Study variables were tabled and compared across lipid groups and age groups. Continuous 
variables are summarized by means with standard deviations or, if substantially skewed, 
were log transformed and summarized by geometric means with first and third quartiles of 
the distribution. The distributions of TG/HDL ratio, non-HDL-C, HOMA, and hsCRP were 
log transformed for testing and modeling. Student’s t-tests or ANOVA F-tests were used to 
evaluate differences in means and Fisher’s exact tests were used to evaluate differences in 
proportions.
Ordinary least squares regression models were used to analyze HOMA and hsCRP as they 
respectively relate to TG/HDL and non-HDL-C, particularly in adults vs. adolescents, while 
adjusting for gender, WC, BMI, systolic BP, and hypertension medications use. First, we 
tested interaction terms between age groups (adult was the reference level) and TG/HDL in 
HOMA and hsCRP models. Then we tested interaction terms between cohort and non-HDL-
C in HOMA and hsCRP models. If determined not statistically significant, the interaction 
terms would be dropped from the models and both TG/HDL and non-HDL-C would be 
entered into the same models of HOMA and hsCRP.
The significance level for all hypothesis testing was set at α <0.05. All statistical analyses 
were conducted using SAS v9.4 (SAS Institute, Cary, NC, USA).
Results
Complete data were available for analysis on 283 adolescents and 484 adults. Table 1 
provides summary data on the adolescent and adult cohorts and compares their BMI, WC, 
HOMA and hsCRP. The adolescents and adults had similar prevalence of obesity (50.2% 
and 51.4%, respectively). HOMA was significantly higher among adolescents than adults 
(1.86 versus 1.55, p < 0.01) and hsCRP was significantly lower among adolescents than 
adults (0.78 versus 1.67, p < 0.01).
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Table 2 provides the TG/HDL ratio groups defined by adult tertiles of TG/HDL ratio and 
compares BMI, WC, HOMA and hsCRP across these tertile-based groups in both 
adolescents and adults. Forty-four of the 283 adolescents (16%) had a TG/HDL ratio above 
2.028 (high adult tertile). In both adolescents and adults, BMI and WC significantly 
increased as TG/HDL ratio increased. The BMI in the high TG/HDL ratio groups was 
comparable with a geometric mean of 34.0 kg/m2 in the adolescents and 32.2 kg/m2 in the 
adults (p = 0.18). Similarly, the waist circumference geometric mean was 100.4 cm in 
adolescents and of 100.9 cm in adults (p = 0.75). Higher TG/HDL ratio was significantly 
related to higher hsCRP in both adolescents (p < 0.01) and adults (p = 0.01). The geometric 
means of hsCRP were not similar when comparing adolescents and adults in the high 
TG/HDL ratio groups (2.04 mg/dl versus 1.53 mg/dl), but the difference was not statistically 
significant (p = 0.12). Higher TG/HDL ratio was significantly related to higher HOMA in 
both adolescents (p = 0.01) and adults (p < 0.01). The geometric means of HOMA were 
significantly higher in the high TG/HDL adolescent cohort compared to the adults (3.36 
mg/dl versus 1.99 mg/dl, p < 0.01).
Table 3 shows the non-HDL-C groups defined by adolescent and adult guidelines and 
compares the study variables of BMI, WC, HOMA and hsCRP by non-HDL-C group. 
Prevalence of elevated non-HDL-C was 22/283 (8%) in adolescents and 60/484 (12%) in 
adults. BMI and WC significantly increased as non-HDL-C increased in both cohorts. The 
BMI geometric means in the high non-HDL-C groups were comparable in adolescents and 
adults (33.1 kg/m2 versus 32.0 kg/m2, respectively). Similarly, the WC geometric means in 
the high non-HDL-C groups were comparably elevated in adolescents versus adults (100.8 
cm versus 101.7 cm, respectively). HsCRP tended to be higher with higher non-HDL-C in 
both adolescents and adults, but not statistically significantly (p = 0.09 and p = 0.07, 
respectively). HOMA also was higher with higher non-HDL-C in adolescents and adults (p 
= 0.03 and p = 0.048).
To further explore these relationships, we fit four exploratory regression models. We 
regressed log transformed hsCRP and log transformed HOMA, respectively, on log 
transformed TG/HDL and log transformed non-HDL-C, respectively, an age group indicator 
variable (adult was the reference), and a term for the interaction with age group while 
adjusting for potential confounding variables. We found that TG/HDL and non-HDL-C do 
not have statistically significant interactions with either hsCRP (TG/HDL-cohort interaction 
p = 0.16; non-HDL-C-cohort interaction p = 0.64) or HOMA (TG/HDL-cohort interaction p 
= 0.77; non-HDL-C-cohort interaction p = 0.62). We then fit two more adjusted regression 
models, one for hsCRP and one for HOMA, including both log transformed dyslipidemia 
markers. In adjusted regression models having TG/HDL, non-HDL-C is not important or 
statistically significant for predicting hsCRP and HOMA (p = 0.84 and p = 0.45, 
respectively). See figure 1 which depicts the unadjusted relationships between log TG/HDL 
and log hsCRP (panel A.) and log HOMA (panel B.). After adjusting for non-HDL-C and 
other covariates, our models suggest that among these adolescents and adults, a 2-fold 
higher TG/HDL ratio was associated with statistically significant higher hsCRP (10.4%; 
95% CI: 1.1% – 20.5%) and HOMA (24.2%: 95% CI: 16.4% – 32.6%).
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Discussion
While studies in both adults and children show strong relationships among dyslipidemia, 
obesity, inflammation, and insulin resistance, no prior study has directly compared the 
quantitative relationships in different age groups. Our data show that when African-
Americans are stratified by TG/HDL ratio or non HDL-C values, there are similar levels of 
metabolic risk in dyslipidemic adolescent and adult African Americans. TG/HDL ratio 
appears to be the main driver of these relationships. Both adolescents and adults demonstrate 
comparable BMI and waist circumference at similar levels of dyslipidemia. HsCRP and 
HOMA were also elevated in adolescents and adults with elevated TG/HDL ratio and non-
HDL-C, but when placed in the same model, only TG/HDL was predictive of hsCRP and 
HOMA. The relationship between HOMA and dyslipidemia appears to be somewhat 
stronger in adolescent versus adult African Americans, while the relationship of hsCRP with 
dyslipidemia may be stronger in adults versus adolescents, but this effect modification was 
not statistically significant in these data.
Metabolic syndrome is a cluster of metabolic and hemodynamic risk factors within 
individuals that markedly increase risk for adverse cardiovascular outcomes. The core 
abnormality that links the risk factors is insulin resistance, or impaired insulin mediated 
glucose uptake,[25, 26]. Insulin resistance, or impaired tissue sensitivity to insulin action, is 
difficult to quantify clinically. The concept of metabolic syndrome has been developed as a 
strategy to identify individuals with multiple cardiovascular disease risk factors that are 
linked with insulin resistance [27, 28]. The clinical utility of the TG/HDL-C ratio in 
predicting insulin resistance and metabolic syndrome has been recently described. A 
TG/HDL ratio of 3.5 or above has been shown to be a simple marker for metabolic 
syndrome and probable cardiovascular disease in adults. Several studies have demonstrated 
that children with a TG/HDL ratio > 3 had significantly higher BMI and waist 
circumference. These authors also noted a racial difference between African American and 
Caucasian children, with a TG/HDL ratio of 2.5 being as accurate in African American 
children as 3 was in Caucasions.[2–5]
The leading theory to explain the mechanism underlying the detrimental effect of insulin 
resistance on cardiovascular injury is the association of insulin resistance with 
atherosclerotic dyslipidemia. Several reports describe greater insulin resistance in African 
Americans compared to Caucasians, including children as well as adults..[29–31] Despite 
having greater insulin resistance, African Americans have more favorable lipid profiles 
compared to Caucasians, with TG and HDL-C concentrations compared to Caucasians.[32, 
33] Consequently, because metabolic syndrome is determined based on set thresholds for 
elevated TG and low HDL-C, the reported prevalence of metabolic syndrome is lower in 
African Americans compared to Caucasians.[34]
Although the more favorable lipid profile observed in African Americans compared to 
Caucasians would suggest lower atherogenic risk, additional studies indicate significant 
metabolic risk among African Americans despite somewhat lower TG and higher HDL-C. In 
a study on young adult African Americans, age 30–45 years, significant correlations were 
found for TG, HDL-C, and TG/HDL-C ratio with insulin resistance, quantified by the 
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insulin clamp procedure. Despite obesity in 50% of that sample, only 10% of participants 
had plasma TG levels ≥150 mg/dL, a level that was a criterion for metabolic syndrome. 
Participants with TG levels from 110 to 149 mg/dL had measures of insulin resistance 
comparable to those with TG >150 mg/dL.[35] Despite a more favorable lipid profile among 
African Americans, it is possible that they have a different threshold for adverse effects of 
relative dyslipidemia. Lipid mediated vascular injury could be mediated through an 
oxidative stress pathway. This theory was investigated by Lopes et al. who investigated the 
effect of acute hyperlipidemia in African Americans and Caucasians. [36] In both African 
American and Caucasian groups, a comparable increase in plasma TG concentration 
occurred following an infusion of Intralipid and heparin. However, F2-isoprostanes, a 
biomarker of oxidative stress in humans, increased significantly more in African Americans 
compared to Caucasians. Although this report is based on a short-term rise in TG, the results 
suggest that African Americans could have greater sensitivity to increases in TG. Some 
reports on metabolic syndrome prevalence, based on studies that include various race 
groups, question the validity of applying the same criteria for metabolic syndrome to all race 
and ethnic groups[37, 38]. In both our adult and adolescent cohorts, the TG/HDL ratio, 
which captures modest increases in TG and modest decreases in HDL-C, may be a better 
indicator of insulin resistance, metabolic syndrome, and heightened atherogenic 
cardiovascular risk in African Americans than considering only TG or HDL-C.
The data demonstrating greater insulin resistance in adolescents compared to adults, present 
across all TG/HDL and non-HDL-C strata may, to some extent, be due to the relative insulin 
resistance of adolescence. Previous clinical studies in healthy adolescents have demonstrated 
the presence of a transient increase in insulin resistance that occurs during normal pubertal 
development.[39–41] The factors that contribute to the changes in insulin action during 
puberty have not been clearly defined. As in adults, insulin resistance in adolescents is 
strongly associated with BMI. However, the relative insulin resistance of puberty is not 
explained by differences in BMI or adiposity.[40]
Obesity-related inflammation has been described in both adults and children. A strong 
correlation between obesity and CRP was reported among middle-age and elderly African 
americans in the Jackson Heart Study.[42] We previously reported similar CRP relationships 
with obesity in our adolescent and young adult African American cohorts. African American 
adolescents with BMI exceeding 30 Kg/m2 had levels of CRP that were similar to obese 
young adult African Americans.[43] [Data from the National Health and Nutrition 
Examination Survey (NHANES) on children and adolescents document a significant 
association of plasma hsCRP level with measures of BMI and skinfold thickness.[44] These 
authors reported significant associations unfavorable changes in metabolic parameters 
among obese adolescents, including increased Tg/HDL ratio. The Cardiovascular Risk in 
Young Finns Study, which obtained longitudinal data from childhood through young 
adulthood, reported that childhood BMI and hsCRP were predictive of adverse health 
consequences in adulthood.[45] Our data that demonstrate comparable levels of hsCRP in 
both adolescents and adults with BMI >30 Kg/m2 suggest the possibility of early adult onset 
of the adverse health consequences of concurrent exposure inflammation with more 
atherogenic lipid status.
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Study limitations
We examined only African Americans, so the trends observed may not be applicable to 
other ethnic groups. The study was cross-sectional and did not determine causality. Tanner 
staging was not done so the impact of stage of puberty on HOMA could not be assessed. 
The study group was drawn from two primary care practices in the same urban hospital so 
the results may not be applicable to African Americans in suburban or rural settings.
Conclusions
Our data demonstrate that elevated TG/HDL ratio is associated with equal if not more 
metabolic risk in adolescents than adult African Americans. Age does not impact adverse 
metabolic profiles related to obesity in African Americans..
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Highlights
“Adolescent and Adult African Americans Have Similar Metabolic Dyslipidemia”
1. Studies comparing adolescents and adults with regard to metabolic disturbances 
related to dyslipidemia have not been performed.
2. African Americans experience metabolic disturbances at lower levels of 
triglycerides than Caucasians.
3. When stratified by triglyceride/HDL-C ratio or by non HDL- C level, adolescent 
African Americans have similar BMI and waist circumference as adults.
4. As triglyceride/HDL-C ratio increases, HOMA and hs CRP increase, the slope 
of this relationship is steeper in adolescents compared to adults.
5. Triglyceride/HDL-C ratio is a more important determinant of metabolic risk 
than non HDL-C.
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Figure 1. 
Log transformed hsCRP (panel A.) and log transformed HOMA (panel B.) by log 
transformed triglyceride/HDL ratio with least squares regression slopes for adolescents and 
adults.
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Table 1
Descriptive statistics on the adolescent and adult participants summarized with frequencies (percentages), 
means (SD), or geometric means [1st quartile, 3rd quartile].
Variable Adult (N=484) Adolescent (N=283) p†
Age (years) 37.73 (7.50) 16.19 (1.68) <.01
Gender, female 242 (50.0%) 136 (48.2%) 0.65
Smoking 300 (62.0%) 9 (3.2%) <.01
Alcohol use 232 (47.9%) 17 (6.1%) <.01
BMI (kg/m2) 30.64 [25.71, 35.42] 28.40 [22.92, 34.66] <.01
WC (cm) 96.87 [86.00,107.00] 86.74 [74.15,101.65] <.01
Obesity** 243 (50.2%) 145 (51.4%) 0.77
SBP (mmHg) 120.66 [110.00, 130.0] 112.99 [105.67, 120.67] <.01
DBP (mmHg) 74.53 [66.00, 82.00] 62.46 [57.67, 67.67] <.01
Heart rate (bpm) 70.39 [64.00, 78.00] 71.07 [64.00, 78.00] 0.35
Hypertensive medications 169 (34.9%) N/A
High BP* 246 (50.8%) 78 (27.7%) <.01
HDL-C (mg/dl) 47.95 (14.75) 52.63 (12.65) <.01
LDL-C (mg/dl) 108.50 (29.18) 88.63 (26.70) <.01
Total cholesterol (mg/dl) 172.77 (32.47) 155.10 (29.89) <.01
Non-HDL-C (mg/dl) 124.82 (31.33) 102.47 (28.93) <.01
Triglycerides (mg/dl) 72.34 [51.00, 97.00] 61.72 [47.00, 77.00] <.01
Triglycerides/HDL-C ratio 1.58 [1.00, 2.38] 1.21 [0.83, 1.60] <.01
Fasting glucose (mg/dl) 103.66 (18.85) 96.91 (10.46) <.01
Fasting insulin (mg/dl) 6.14 [3.55, 9.70] 7.84 [4.70, 12.50] <.01
Metabolic syndrome‡ 126 (26.0%) 39 (13.8%) <.01
hsCRP (mg/dl) 1.67 [0.90, 3.95] 0.78 [0.30, 2.20] <.01
HOMA (mg/dl) 1.55 [0.85, 2.48] 1.86 [1.12, 2.93] <.01
†
Fishers exact test (categorical) or Students t-test (continuous);
*
High BP: SBP ≥120/80 mmHg (adolescents) or ≥130/85 or HTN Rx (adults);
**Obesity: >=95th percentile (adolescents), >=30 BMI (adults);
‡
Metabolic Syndrome: 3 or more of following: Waist circumference ≥102 cm (males) or ≥88 (females), SBP ≥120/80 mmHg (adolescents) or 
≥130/85 or hypertension medications use (adults), HDL <40 mg/dl (males) or <50 (females), Triglycerides ≥110 mg/dl (adolescents) or ≥150 
(adults), Fasting glucose ≥110 mg/dl.
Abbreviations
SD = Standard Deviation
BMI = body mass index
WC = waist circumference
SBP = systolic blood pressure
DBP = diastolic blood pressure
HDL-C = high density lipoprotein cholesterol
LDL-C = low density lipoprotein cholesterol
hsCRP = high sensitivity c-reactive protein
HOMA = homeostasis model of insulin resistance
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